PE20050292A1 - Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion y su empleo como medicamentos - Google Patents

Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion y su empleo como medicamentos

Info

Publication number
PE20050292A1
PE20050292A1 PE2004000203A PE2004000203A PE20050292A1 PE 20050292 A1 PE20050292 A1 PE 20050292A1 PE 2004000203 A PE2004000203 A PE 2004000203A PE 2004000203 A PE2004000203 A PE 2004000203A PE 20050292 A1 PE20050292 A1 PE 20050292A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
methyl
ppar
aril
Prior art date
Application number
PE2004000203A
Other languages
English (en)
Spanish (es)
Inventor
Christian Stapper
Stefanie Keil
Heiner Glombik
Eugen Falk
Jochen Goerlitzer
Dirk Gretzke
Hans-Ludwig Schaefer
Wolfgang Wendler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20050292A1 publication Critical patent/PE20050292A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PE2004000203A 2003-02-27 2004-02-27 Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion y su empleo como medicamentos PE20050292A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
PE20050292A1 true PE20050292A1 (es) 2005-05-24

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2004000206A PE20040959A1 (es) 2003-02-27 2004-02-27 Derivados de acido acetico sustituido con cicloalquilmetoxi y procedimientos para su preparacion
PE2004000203A PE20050292A1 (es) 2003-02-27 2004-02-27 Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion y su empleo como medicamentos
PE2004000205A PE20050293A1 (es) 2003-02-27 2004-02-27 Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2004000206A PE20040959A1 (es) 2003-02-27 2004-02-27 Derivados de acido acetico sustituido con cicloalquilmetoxi y procedimientos para su preparacion

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2004000205A PE20050293A1 (es) 2003-02-27 2004-02-27 Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos

Country Status (34)

Country Link
US (5) US7259177B2 (US07259177-20070821-C00164.png)
EP (3) EP1599452B1 (US07259177-20070821-C00164.png)
JP (3) JP2006519199A (US07259177-20070821-C00164.png)
KR (3) KR20050105492A (US07259177-20070821-C00164.png)
CN (3) CN100398526C (US07259177-20070821-C00164.png)
AR (3) AR043427A1 (US07259177-20070821-C00164.png)
AT (3) ATE365159T1 (US07259177-20070821-C00164.png)
AU (3) AU2004215672B2 (US07259177-20070821-C00164.png)
BR (3) BRPI0407758A (US07259177-20070821-C00164.png)
CA (3) CA2516620A1 (US07259177-20070821-C00164.png)
CL (2) CL2004000392A1 (US07259177-20070821-C00164.png)
CO (2) CO5690580A2 (US07259177-20070821-C00164.png)
DE (4) DE10308355A1 (US07259177-20070821-C00164.png)
DK (3) DK1599452T3 (US07259177-20070821-C00164.png)
EC (2) ECSP055985A (US07259177-20070821-C00164.png)
ES (3) ES2329366T3 (US07259177-20070821-C00164.png)
HR (3) HRP20050744A2 (US07259177-20070821-C00164.png)
IL (2) IL170316A (US07259177-20070821-C00164.png)
MA (3) MA27737A1 (US07259177-20070821-C00164.png)
MX (3) MXPA05008988A (US07259177-20070821-C00164.png)
NO (3) NO20054408L (US07259177-20070821-C00164.png)
OA (2) OA13034A (US07259177-20070821-C00164.png)
PA (1) PA8596801A1 (US07259177-20070821-C00164.png)
PE (3) PE20040959A1 (US07259177-20070821-C00164.png)
PL (3) PL378437A1 (US07259177-20070821-C00164.png)
PT (3) PT1599455E (US07259177-20070821-C00164.png)
RS (1) RS20050594A (US07259177-20070821-C00164.png)
RU (3) RU2005129992A (US07259177-20070821-C00164.png)
SA (1) SA04250153A (US07259177-20070821-C00164.png)
TN (2) TNSN05204A1 (US07259177-20070821-C00164.png)
TW (3) TW200500349A (US07259177-20070821-C00164.png)
UY (2) UY28210A1 (US07259177-20070821-C00164.png)
WO (3) WO2004076427A1 (US07259177-20070821-C00164.png)
ZA (2) ZA200505765B (US07259177-20070821-C00164.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit ι-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 FormulaciĂłn y proceso de compresiĂłn directa
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
KR101398715B1 (ko) 2006-08-10 2014-05-27 가부시키가이샤 미모잭스 아카시아속 나무 껍질 유래물을 함유하는 혈당 강하 조성물
CN101801906A (zh) 2007-08-16 2010-08-11 索尔维公司 制备4-氟取代的3-氧代-烷酸酯的方法
HUE027833T2 (en) 2008-02-29 2016-11-28 Nissan Chemical Ind Ltd Process for the preparation of a thiophene derivative and its intermediate
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116184782A (zh) 2017-12-13 2023-05-30 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
EP0876379A1 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
PT944648E (pt) 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
CN1190434C (zh) 1996-12-31 2005-02-23 雷迪实验室有限公司 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
RU2215004C2 (ru) 1997-07-16 2003-10-27 Ново Нордиск А/С Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
KR100620337B1 (ko) * 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
AU5443499A (en) * 1998-08-27 2000-03-21 Ono Pharmaceutical Co. Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
AU3956900A (en) 1999-04-16 2000-11-02 Boehringer Ingelheim International Gmbh Substituted imidazoles, their preparation and use
JP2002543065A (ja) * 1999-04-28 2002-12-17 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ppap受容体リガンドとしてのトリアリール酸誘導体
HUP0201291A3 (en) 1999-04-28 2002-11-28 Sanofi Aventis Deutschland Di-aryl acid derivatives as ppar receptor ligands and pharmaceutical compositions containing them
US6284766B1 (en) 1999-04-30 2001-09-04 Neurogen Corporation 9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
DE60029446T2 (de) 1999-06-18 2007-02-08 Merck & Co., Inc. Arylthiazolidindione und aryloxazolidindion-derivate
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
MXPA02000973A (es) 1999-07-29 2002-07-30 Lilly Co Eli Benzofurilpiperazinas y benzofurilhomopiperazinas: agonistas de serotonina.
ATE302754T1 (de) 1999-09-01 2005-09-15 Aventis Pharma Gmbh Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
WO2001040171A1 (en) 1999-12-03 2001-06-07 Astrazeneca Ab Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
US6500804B2 (en) 2000-03-31 2002-12-31 Probiodrug Ag Method for the improvement of islet signaling in diabetes mellitus and for its prevention
EA004244B1 (ru) 2000-04-25 2004-02-26 Киорин Фармасьютикал Ко., Лтд. Новый стабильный кристалл производного тиазолидиндиона и способ его получения
AU2001252574B2 (en) 2000-04-28 2005-03-17 Asahi Kasei Pharma Corporation Novel bicyclic compounds
WO2001085695A1 (en) 2000-05-11 2001-11-15 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
CA2410597A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
NZ523034A (en) 2000-06-09 2004-07-30 Aventis Pharma Gmbh Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
DE60128239T2 (de) * 2000-08-23 2008-01-10 Eli Lilly And Co., Indianapolis Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
EP1313715B1 (en) 2000-08-23 2007-08-01 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU2002222573A1 (en) 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
SK7822003A3 (en) 2000-12-21 2003-12-02 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
CZ20031772A3 (cs) * 2000-12-25 2003-11-12 Ono Pharmaceutical Co., Ltd. Derivát dihydronaftalenu a činidlo obsahující tento derivát jako účinnou složku
MXPA03007284A (es) 2001-02-15 2003-12-04 Pfizer Prod Inc Agonistas de receptor activador del proliferador de peroxisomas.
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
CZ20033328A3 (cs) * 2001-06-07 2004-06-16 Eli Lilly And Company Modulåtory receptorů aktivovaných proliferåtory peroxisomů (PPAR)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
IL160556A0 (en) 2001-08-31 2004-07-25 Aventis Pharma Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
ATE433440T1 (de) 2002-02-05 2009-06-15 Lilly Co Eli Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
EP1656368A4 (en) 2002-07-09 2009-08-26 Bristol Myers Squibb Co SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AGENTS AND ANTIABESITY AND THEIR MANUFACTURING PROCESS
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
AU2004215677A1 (en) 2004-09-10
KR20050105492A (ko) 2005-11-04
CN1753879A (zh) 2006-03-29
PT1599453E (pt) 2009-07-14
EP1599453B1 (de) 2009-05-06
JP2006519193A (ja) 2006-08-24
TW200508210A (en) 2005-03-01
US7259177B2 (en) 2007-08-21
MXPA05008988A (es) 2005-10-18
PE20040959A1 (es) 2005-01-17
BRPI0407907A (pt) 2006-02-14
ECSP055985A (es) 2006-01-16
HRP20050744A2 (en) 2006-09-30
CN100439345C (zh) 2008-12-03
PT1599455E (pt) 2009-09-29
AR043433A1 (es) 2005-07-27
CL2004000391A1 (es) 2005-01-07
MA27742A1 (fr) 2006-02-01
DK1599452T3 (da) 2007-10-01
AU2004215677B2 (en) 2010-01-07
ES2329366T3 (es) 2009-11-25
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
MXPA05008951A (es) 2005-11-04
TNSN05206A1 (en) 2007-06-11
ECSP055986A (es) 2006-01-16
CA2517386A1 (en) 2004-09-10
IL170314A (en) 2010-11-30
DK1599455T3 (da) 2009-11-09
WO2004076427A1 (de) 2004-09-10
UY28209A1 (es) 2004-09-30
CN100439347C (zh) 2008-12-03
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
DK1599453T3 (da) 2009-08-24
US7872034B2 (en) 2011-01-18
CN100398526C (zh) 2008-07-02
ES2326418T3 (es) 2009-10-09
DE10308355A1 (de) 2004-12-23
EP1599455B1 (de) 2009-07-01
PL378130A1 (pl) 2006-03-06
MA27737A1 (fr) 2006-02-01
CA2516620A1 (en) 2004-09-10
DE502004004139D1 (de) 2007-08-02
EP1599453A1 (de) 2005-11-30
KR20050106461A (ko) 2005-11-09
PL378437A1 (pl) 2006-04-03
EP1599455A1 (de) 2005-11-30
JP2006519199A (ja) 2006-08-24
HRP20050742A2 (en) 2006-09-30
TNSN05204A1 (en) 2007-06-11
OA13035A (en) 2006-11-10
BRPI0407758A (pt) 2006-02-14
UY28210A1 (es) 2004-09-30
SA04250153A (ar) 2005-12-03
MA27736A1 (fr) 2006-02-01
OA13034A (en) 2006-11-10
CN1756748A (zh) 2006-04-05
ZA200505765B (en) 2006-05-31
BRPI0407814A (pt) 2006-02-14
RU2005129992A (ru) 2006-02-10
ATE365159T1 (de) 2007-07-15
MXPA05008995A (es) 2005-10-18
US20080167354A1 (en) 2008-07-10
NO20054398L (no) 2005-11-02
CO5690578A2 (es) 2006-10-31
AU2004215673A1 (en) 2004-09-10
DE502004009453D1 (de) 2009-06-18
EP1599452A1 (de) 2005-11-30
PE20050293A1 (es) 2005-05-24
NO20054398D0 (no) 2005-09-22
CA2517381A1 (en) 2004-09-10
ZA200505768B (en) 2005-11-23
PT1599452E (pt) 2007-09-12
TW200500349A (en) 2005-01-01
AR043432A1 (es) 2005-07-27
DE502004009690D1 (de) 2009-08-13
US20080015238A1 (en) 2008-01-17
NO20054408D0 (no) 2005-09-22
CL2004000392A1 (es) 2005-04-22
US7335671B2 (en) 2008-02-26
NO20054396D0 (no) 2005-09-22
AR043427A1 (es) 2005-07-27
PL377735A1 (pl) 2006-02-20
CO5690580A2 (es) 2006-10-31
AU2004215672A1 (en) 2004-09-10
US20040209920A1 (en) 2004-10-21
EP1599452B1 (de) 2007-06-20
WO2004076428A1 (de) 2004-09-10
ES2287700T3 (es) 2007-12-16
US20050101637A1 (en) 2005-05-12
AU2004215672B2 (en) 2010-01-07
RU2005129995A (ru) 2006-01-27
WO2004076426A1 (de) 2004-09-10
RS20050594A (en) 2007-12-31
KR20050106462A (ko) 2005-11-09
TW200510352A (en) 2005-03-16
CN1753881A (zh) 2006-03-29
JP2006519194A (ja) 2006-08-24
RU2005130002A (ru) 2006-01-27
ATE435217T1 (de) 2009-07-15
US20050215596A1 (en) 2005-09-29
ATE430738T1 (de) 2009-05-15
NO20054396L (no) 2005-11-11
AU2004215673B2 (en) 2009-10-01
US7365084B2 (en) 2008-04-29

Similar Documents

Publication Publication Date Title
PE20050292A1 (es) Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion y su empleo como medicamentos
PE20090328A1 (es) Derivados de oxadiazol como moduladores de los receptores metabotropicos de glutamato
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20121474A1 (es) Nuevos compuestos de espiropiperidina
PE20140207A1 (es) Composiciones y metodos para modular el fxr
PE20060640A1 (es) Derivados del acido alcanoico arilcicloalquil-sustituidos y procedimientos para su preparacion
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20081487A1 (es) DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1
AR087196A1 (es) Metodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales ii
AR020851A2 (es) Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20061295A1 (es) Derivados de acetileno
PE20080970A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
AR078756A1 (es) Moduladores alostericos positivos (map)
AR059428A1 (es) Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende.
ATE493404T1 (de) Azabicyclo-(3,1,0)-hexan-derivate als modulatoren von dopamin-d3-rezeptoren
DE602006018152D1 (de) Triazolderivate als modulatoren von dopamin-d3-rezeptoren
PE20061348A1 (es) DERIVADOS DEL ACIDO PIRMIDINCARBOXILICO COMO MODULADORES DE PPAR-alfa
PE20071251A1 (es) Derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
PE20040913A1 (es) Enantiomeros (r) y (s) de derivados del acido tiofeno hidroxamico como inhibidores de desacetilasa histona (hdac)
AR073565A1 (es) Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen
AR073609A1 (es) COMPUESTOS DE ANILLO FUSIONADO Y USO DE LOS MISMOS EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVACIoN DE LA GLUCOQUINASA.

Legal Events

Date Code Title Description
FC Refusal